Tomoaki Ishigami

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 5

Top Topics

Mild Cognitive Impairment

Top Venues

Journal of molecular medicine (Berlin, Germany)

This page only lists publications with an associated author ORCID identifier.

Publications

Kazushi Uneda, Yuki Kawai, Akira Kaneko, Takumi Kayo, Shuichiro Akiba, Tomoaki Ishigami, Hiromi Yoshida-Komiya, Masao Suzuki, Tadamichi Mitsuma
Analysis of clinical factors associated with Kampo formula-induced pseudoaldosteronism based on self-reported information from the Japanese Adverse Drug Event Report database. PloS one 19 (1) (2024)
Kazushi Uneda, Yuki Kawai, Akira Kaneko, Takumi Kayo, Shuichiro Akiba, Tomoaki Ishigami, Hiromi Yoshida-Komiya, Masao Suzuki, Tadamichi Mitsuma
Analysis of clinical factors associated with Kampo formula-induced pseudoaldosteronism based on self-reported information from the Japanese Adverse Drug Event Report database. PloS one 19 (1) (2024)
Kazushi Uneda, Yuki Kawai, Akira Kaneko, Takumi Kayo, Shuichiro Akiba, Tomoaki Ishigami, Hiromi Yoshida-Komiya, Masao Suzuki, Tadamichi Mitsuma
Analysis of clinical factors associated with Kampo formula-induced pseudoaldosteronism based on self-reported information from the Japanese Adverse Drug Event Report database. PloS one 19 (1) (2024)
Lin Chen, Tomoaki Ishigami, Hiroshi Doi, Kentaro Arakawa, Kouichi Tamura
Gut microbiota and atherosclerosis: role of B cell for atherosclerosis focusing on the gut-immune-B2 cell axis. Journal of molecular medicine (Berlin, Germany) 98 (9) (2020)
Kentaro Arakawa, Tomoaki Ishigami, Michiko Nakai-Sugiyama, Lin Chen, Hiroshi Doi, Tabito Kino, Shintaro Minegishi, Sae Saigoh-Teranaka, Rie Sasaki-Nakashima, Kiyoshi Hibi, Kazuo Kimura, Kouichi Tamura
Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PloS one 14 (6) (2019)